View Filing Data

Print Document View Excel Document

Document And Entity Information - shares	6 Months Ended
Document And Entity Information - shares	Jun. 30, 2014	Jul. 25, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	Sucampo Pharmaceuticals, Inc.
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		44,293,899
Amendment Flag	false
Entity Central Index Key	0001365216
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Jun. 30, 2014
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q2

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2014	Dec. 31, 2013
Common Class A [Member]
Stockholders' equity:
Common stock value	$ 442	$ 432
Cash and cash equivalents	53,532	44,102
Investments, current	14,017	16,003
Product royalties receivable	13,888	14,829
Unbilled accounts receivable	3	1
Accounts receivable, net	4,755	5,407
Prepaid and income taxes receivable	545	9
Deferred tax assets, current	1,988	2,028
Deferred charge, current	673	673
Restricted cash, current	26,129	26,115
Inventory	423	209
Prepaid expenses and other current assets	3,396	3,977
Total current assets	119,349	113,353
Investments, non-current	7,460	7,219
Property and equipment, net	979	1,156
Intangible assets, net	5,949	6,438
Deferred tax assets, non-current	1,275	1,212
Deferred charge, non-current	4,204	4,540
Restricted cash, non-current	2,471	2,471
Other assets	552	488
Total assets	142,239	136,877
Accounts payable	5,623	7,614
Accrued expenses	6,264	5,682
Deferred revenue, current	1,794	1,365
Income tax payable	35	701
Notes payable, current	27,790	26,892
Other current liabilities	1,013	358
Total current liabilities	42,519	42,612
Notes payable, non-current	21,741	25,828
Deferred revenue, non-current	5,824	6,169
Deferred tax liability, non-current	1,223	2,066
Other liabilities	1,559	1,233
Total liabilities	72,866	77,908
Commitments and contingencies (Note 7)
Additional paid-in capital	80,377	72,109
Accumulated other comprehensive income	15,361	15,601
Treasury stock, at cost; 524,792 and 524,792 shares	(2,313)	(2,313)
Accumulated deficit	(24,494)	(26,860)
Total stockholders' equity	69,373	58,969
Total liabilities and stockholders' equity	$ 142,239	$ 136,877

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2014	Dec. 31, 2013
Common Class A [Member]
Common stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	270,000,000	270,000,000
Common stock, shares issued	44,293,899	43,315,749
Common stock, shares outstanding	44,293,899	43,315,749
Common Class B [Member]
Common stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	75,000,000	75,000,000
Common stock, shares issued	0	0
Common stock, shares outstanding	0	0
Preferred stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Preferred stock,shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Treasury stock, shares	524,792	524,792

Condensed Consolidated Statements of Operations and Comprehensive Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Revenues:
Research and development revenue	$ 1,700	$ 11,461	$ 3,484	$ 14,261
Product royalty revenue	13,888	12,000	27,389	23,677
Product sales revenue	7,543	3,399	13,855	5,616
Co-promotion revenue	723		1,085	61
Contract and collaboration revenue	215	163	417	327
Total revenues	24,069	27,023	46,230	43,942
Costs and expenses:
Costs of goods sold	3,796	1,908	7,189	3,190
Research and development	4,252	4,425	9,387	10,054
General and administrative	8,197	5,968	15,454	13,195
Selling and marketing	4,013	4,553	7,660	9,942
Total costs and expenses	20,258	16,854	39,690	36,381
Income from operations	3,811	10,169	6,540	7,561
Non-operating income (expense):
Interest income	23	23	80	42
Interest expense	(392)	(493)	(792)	(988)
Other income (expense), net	(53)	870	(376)	2,020
Total non-operating income (expense), net	(422)	400	(1,088)	1,074
Income before income taxes	3,389	10,569	5,452	8,635
Income tax provision	(1,779)	(4,324)	(3,086)	(5,466)
Net income	$ 1,610	$ 6,245	$ 2,366	$ 3,169
Net income per share:
Basic (in Dollars per share)	$ 0.04	$ 0.15	$ 0.05	$ 0.08
Diluted (in Dollars per share)	$ 0.04	$ 0.15	$ 0.05	$ 0.07
Weighted average common shares outstanding:
Basic (in Shares)	43,640	41,604	43,521	41,533
Diluted (in Shares)	43,640	42,868	43,609	42,597
Comprehensive income:
Net income	$ 1,610	$ 6,245	$ 2,366	$ 3,169
Other comprehensive income (loss):
Unrealized loss on investments, net of tax effect	(3)	(19)	5	(34)
Foreign currency translation	(126)	(186)	(245)	(134)
Comprehensive income	$ 1,481	$ 6,040	$ 2,126	$ 3,001

Condensed Consolidated Statement of Changes in Stockholders’ Equity (Unaudited) - 6 months ended Jun. 30, 2014 - USD ($) $ in Thousands	Common Class A [Member] Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Treasury Stock [Member]	Retained Earnings [Member]	Total
Balance, amount at Dec. 31, 2013	$ 432	$ 72,109	$ 15,601	$ (2,313)	$ (26,860)	$ 58,969
Balance, shares (in Shares) at Dec. 31, 2013	43,315,749			524,792
Employee stock option expense		832				832
Stock issued under exercise of stock options	$ 4	2,021				2,025
Stock issued under exercise of stock options (in Shares)	437,640
Stock issued under employee stock purchase plan		13				13
Stock issued under employee stock purchase plan (in Shares)	1,989
Stock issued under "at-the-market" offering	$ 6	5,321				5,327
Stock issued under "at-the-market" offering (in Shares)	538,521
Foreign currency translation			(245)			(245)
Unrealized loss on investments, net of tax effect			5			5
Windfall tax benefit from stock-based compensation		81				81
Net income					2,366	2,366
Balance, amount at Jun. 30, 2014	$ 442	$ 80,377	$ 15,361	$ (2,313)	$ (24,494)	$ 69,373
Balance, shares (in Shares) at Jun. 30, 2014	44,293,899			524,792

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Cash flows from operating activities:
Net income	$ 2,366	$ 3,169
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation and amortization	721	753
Deferred tax provision	(792)	(988)
Deferred charge	336	336
Stock-based compensation	832	1,012
Amortization of premiums on investments	50	53
Unrealized currency translations	320	(702)
Changes in operating assets and liabilities:
Accounts receivable	652	(2,256)
Unbilled accounts receivable	(2)	732
Product royalties receivable	941	2,175
Inventory	(211)	(4,832)
Prepaid and income taxes receivable and payable, net	(1,209)	4,797
Accounts payable	(2,006)	294
Accrued expenses	548	(3,993)
Deferred revenue	(1)	(2,777)
Accrued interest payable	(21)	(22)
Other assets and liabilities, net	1,571	(2,355)
Net cash provided by (used in) operating activities	4,095	(4,604)
Cash flows from investing activities:
Purchases of investments	(4,515)	(2,399)
Proceeds from the sales of investments	1,700
Maturities of investments	4,500	5,060
Purchases of property and equipment	(49)	(140)
Changes in restricted cash		(9,561)
Net cash provided by (used in) investing activities	1,636	(7,040)
Cash flows from financing activities:
Proceeds from notes payable		10,600
Repayment of notes payable	(3,906)	(3,725)
Proceeds from exercise of stock options	2,025	1,539
Proceeds from employee stock purchase plan	13	11
Proceeds from "at-the-market" stock issuance	5,327
Purchase of treasury stock		(336)
Windfall benefit from stock-based compensation	81	318
Net cash provided by financing activities	3,540	8,407
Effect of exchange rates on cash and cash equivalents	159	(1,497)
Net increase (decrease) in cash and cash equivalents	9,430	(4,734)
Cash and cash equivalents at beginning of period	44,102	52,022
Cash and cash equivalents at end of period	$ 53,532	$ 47,288

Note 1 - Business Organization and Basis of Presentation

6 Months Ended

Jun. 30, 2014

Disclosure Text Block [Abstract]

Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]

1. Business Organization and Basis of Presentation

Description of the Business

Sucampo Pharmaceuticals, Inc., or the Company, is a global biopharmaceutical company focused on innovative research; discovery, development and commercialization of proprietary drugs to treat gastrointestinal, ophthalmic, neurologic, and oncology-based inflammatory disorders; and is also considering other potential therapeutic applications of the Company’s drug technologies.

The Company currently generates revenue mainly from product royalties, development milestone payments, product sales and clinical development activities. The Company expects to continue to incur significant expenses for the next several years as the Company continues its research and development activities, seeks regulatory approvals and additional indications for approved products and other compounds, and seeks partnering opportunities for the approved products and compounds on a global basis.

In the United States, AMITIZA® (lubiprostone) is marketed for three gastrointestinal indications under the October 2004 collaboration and license agreement, or the Takeda Agreement, with Takeda Pharmaceutical Company Limited, or Takeda. These indications are chronic idiopathic constipation, or CIC, in adults, irritable bowel syndrome with constipation, or IBS-C, in adult women, and opioid-induced constipation, or OIC, in adults. Takeda also holds marketing rights to AMITIZA in Canada and has taken steps to file for regulatory approval in Canada. The Company is primarily responsible for clinical development activities under the Takeda Agreement, while Takeda is primarily responsible for the commercialization of AMITIZA in the United States and Canada. The Company and Takeda initiated commercial sales of AMITIZA in the United States for the treatment of CIC, IBS-C, and OIC in April 2006, May 2008 and May 2013, respectively.

In Japan, AMITIZA is marketed under a license, commercialization and supply agreement, or the Abbott Agreement, with Abbott Japan Co. Ltd., or Abbott, for the gastrointestinal indication of chronic constipation, or CC, excluding constipation caused by organic diseases. Abbott initiated commercial sales of AMITIZA in Japan for the treatment of CC in November 2012. In early December 2013, the two-week limitation on prescriptions, generally applied to all new approvals of products for the first year after reimbursement price approval by the Japanese government was removed. AMITIZA is Japan’s only prescription medicine for CC.

In Switzerland, the Company is commercializing AMITIZA for CIC. The Company announced in February 2014 that the Bundesamt fur Gesundheit revised several reimbursement limitations with which AMITIZA was first approved for reimbursement and inclusion in the Specialitätenliste to allow all Swiss physicians to prescribe AMITIZA to patients who have failed previous treatments with at least two laxatives over a nine month period. In July 2014, the Company announced that Swissmedic, the Swiss Agency for Therapeutic Products, approved AMIITZA for the treatment of OIC in chronic, non-cancer adult patients.

In the United Kingdom, the Company is commercializing AMITIZA for CIC. In July 2014, the Company announced that the National Institute for Health and Care Excellence had published the technology appraisal guidance recommending of the use of AMITIZA in the treatment of CIC and associated symptoms in adults who have failed previous treatments with laxatives. The Company filed for the OIC indication in the United Kingdom and in March 2014, the Company received notification from Medicines and Healthcare Products Regulatory Agency, or MHRA, that the application was not approved. The Company is in continued discussion with MHRA exploring all available options. The Company will be seeking approval for AMITIZA for the CIC indication in other European Union countries following the Mutual Recognition Procedure.

The Company holds license agreements for RESCULA® (unoprostone isopropyl ophthalmic solution) 0.15% in the United States and Canada and the rest of the world, with the exception of Japan, Korea, Taiwan and the People’s Republic of China. The Company is commercializing RESCULA for the lowering of intraocular pressure, or IOP, in patients with open-angle glaucoma or ocular hypertension. According to the U.S. approved product labeling, RESCULA may be used as a first-line agent or concomitantly with other topical ophthalmic drug products to lower intraocular pressure. RESCULA is a BK channel activator, which is different from other available IOP lowering agents.

The Company’s other clinical development programs include the following:

Lubiprostone Reformulation for Pediatric Functional Constipation

As announced previously, Takeda has agreed to fund 100% of the costs for additional reformulation work for lubiprostone. Feasibility testing for this work is ongoing and is expected to be completed in the fourth quarter of 2014. If successful, the reformulation will enable future studies of lubiprostone in adults and younger children who may not be able to swallow the current soft gelatin capsule formulation. Currently, two of the four planned phase 3 studies for the pediatric functional constipation development program are ongoing, both of which are testing the current soft gelatin capsule formulation of lubiprostone in patients 6 to 17 years of age: a 12-week, randomized, placebo-controlled trial that initiated in December 2013 and a follow-on, long-term safety extension study that initiated in March 2014.

Intravenous and Oral Ion Channel Activators for Lumbar Spinal Stenosis

Two ion channel activators, in both the intravenous, or IV, and oral forms, are in clinical development for the treatment of lumbar spinal stenosis, or LSS. Positive top-line results from a phase 1b trial evaluating the safety and pharmacokinetics of the orally administered ion channel activator demonstrated the compound to be generally well-tolerated. This trial is expected to conclude in the third quarter of 2014. The Company plans to conduct an additional phase 2a trial in the second half of 2014 to evaluate the clinical effectiveness of the IV ion channel activator with LSS.

Cobiprostone as an Oral Spray for Oral Mucositis

The Company completed a phase 1b clinical trial for the target indication of prevention and/or treatment of oral mucositis. The results of the phase 1b trial showed that cobiprostone was well-tolerated and revealed low systemic exposure. The next phase of clinical development, a phase 2a trial, is expected to begin in the second half of 2014.

Basis of Presentation

The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America, or GAAP, and the rules and regulations of the Securities and Exchange Commission, or SEC, for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the Company’s Consolidated Financial Statements as of and for the year ended December 31, 2013 included in the Company’s Annual Report on Form 10-K, which was filed with the SEC on March 12, 2014. The financial information as of June 30, 2014 and for the three and six months ended June 30, 2014 and June 30, 2013 is unaudited. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. In the opinion of the Company’s management, all adjustments, consisting only of normal recurring adjustments or accruals, considered necessary for a fair statement of the results of these interim periods have been included. The results of the Company’s operations for any interim period are not necessarily indicative of the results that may be expected for any other interim period or for a full fiscal year.

The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries: Sucampo AG, or SAG, based in Zug, Switzerland, through which the Company conducts certain of its worldwide and European operations; Sucampo Pharma, Ltd., based in Tokyo and Osaka, Japan, through which the Company conducts its Asian operations; Sucampo Pharma Americas LLC, based in Bethesda, Maryland, through which the Company conducts its North and South American operations; and Sucampo Pharma Europe, Ltd., based in Oxford, United Kingdom. The Company liquidated Ambrent Investments S.à r.l., based in Luxembourg, at the end of 2013. All significant inter-company balances and transactions have been eliminated.

The preparation of financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Revisions to Previously Issued Financial Statements

The Company has revised the Condensed Consolidated Statements of Operations and Comprehensive Income for the three and six months ended June 30, 2013 to correct errors in the presentation of gross profit, other income and income taxes. As a result of this revision, gross profit will be removed as a sub-total and costs of goods sold will be disclosed as an operating cost under the heading “Costs and expenses”. Gross profit was presented on the Condensed Consolidated Statements of Operations and Comprehensive Income beginning in the period ended December 31, 2012 and for periods ended March 31, June 30 and September 30, 2013.

In addition, the Company has revised the Condensed Consolidated Statements of Operations and Comprehensive Income for the three and six months ended June 30, 2013 and the Condensed Consolidated Balance Sheet as of December 31, 2013 to correct errors in the recognition of indirect taxes at its Swiss subsidiary. The errors affect the years ended December 31, 2012 and 2013 and the periods ended March 31, 2013, June 30, 2013, September 30, 2013 and March 31, 2014. During those periods, the Company overstated its indirect tax liability and understated net income.

The Company has also revised the Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2013 to correct errors in the classification of foreign exchange gains and losses in net cash used in operating activities, investing activities and the effect of exchange rates on cash and cash equivalents and the change in net income. The errors in classification affect the year ended December 31, 2013 and the periods ended September 30, 2013, June 30, 2013 and March 31, 2013. These errors have no effect on the balances of cash and cash equivalents.

The revisions were determined to not be material, individually or in the aggregate, to any previously issued financial statements. Accordingly, the Company will revise previously reported interim and annual periods in future filings. The following revisions have been made to the previously reported June 30, 2013 balances:

	Presentation as of three months ended June 30, 2013
(In thousands, except per share data)	As Previously Reported			Revision Adjustment			As Revised
Gross profit	$	25,115		$	(25,115	)	$	-
Total costs and expenses		(14,946	)		(1,908	)		(16,854	)
Other income (expense), net		744			126			870
Total non-operating income (expense), net		274			126			400
Income (loss) before income taxes		10,443			126			10,569
Net income		6,119			126			6,245
Net income per share: Diluted		0.14			0.01			0.15
Comprehensive income		5,914			126			6,040

	Presentation as of six months ended June 30, 2013
(In thousands, except per share data)	As Previously Reported			Revision Adjustment			As Revised
Gross profit	$	40,752		$	(40,752	)	$	-
Total costs and expenses		(33,191	)		(3,190	)		(36,381	)
Other income (expense), net		1,825			195			2,020
Total non-operating income (expense), net		879			195			1,074
Income (loss) before income taxes		8,440			195			8,635
Net income		2,974			195			3,169
Net income per share: Basic		0.07			0.01			0.08
Comprehensive income		2,806			195			3,001

Net cash provided by (used in) operating activities		(5,902	)		1,298			(4,604	)
Net cash provided by (used in) investing activities		(7,506	)		466			(7,040	)
Effect of exchange rates on cash and cash equivalents		267			(1,764	)		(1,497	)

	Presentation as of December 31, 2013
(In thousands)	As Previously Reported			Revision Adjustment			As Revised
Other assets	$	584		$	(96	)	$	488
Total assets		136,973			(96	)		136,877
Other liabilities		2,150			(917	)		1,233
Total liabilities		78,825			(917	)		77,908
Accumulated deficit		(27,681	)		821			(26,860	)
Total stockholders' equity		58,148			821			58,969

Note 2 - Summary of Significant Accounting Policies	6 Months Ended
Note 2 - Summary of Significant Accounting Policies	Jun. 30, 2014
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies Restricted Cash Restricted cash primarily represents collateral pledged to support a loan agreement with The Bank of Tokyo-Mitsubishi UFJ, Ltd., or the Tokyo-Mitsubishi Bank; a loan agreement with The Mizuho Bank, Ltd., or the Mizuho Bank; a loan agreement between Numab AG, or Numab, and Zurcher Kantonalbank, under which the Company serves as guarantor; and operating leases with certain financial institutions. Restricted cash totaled approximately $28.6 million at both June 30, 2014 and December 31, 2013. Certain Risks, Concentrations and Uncertainties Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash and cash equivalents, restricted cash, investments and receivables. The Company places its cash, cash equivalents and restricted cash with highly rated financial institutions and invests its excess cash in highly rated investments. As of June 30, 2014 and December 31, 2013, approximately $21.7 million, or 20.9%, and $16.4 million, or 17.1%, respectively, of the Company’s cash, cash equivalents, restricted cash and investments were issued or insured by the United States government or United States government agencies. The Company has not experienced any losses on these accounts related to amounts in excess of insured limits. Revenues from Takeda, an unrelated party, accounted for 68.1% and 87.3% of the Company’s total revenues for the three months ended June 30, 2014 and 2013, respectively, and 69.6% and 87.1% for the six months ended June 30, 2014 and 2013, respectively. Accounts receivable, unbilled accounts receivable and product royalties receivable from Takeda accounted for 80.8% and 88.2% of the Company’s total accounts receivable, unbilled accounts receivable and product royalties receivable at June 30, 2014 and December 31, 2013, respectively. Revenues from another unrelated party, Abbott, accounted for 30.0% and 12.1% of the Company’s total revenues for the three months ended June 30, 2014 and 2013, respectively, and 28.8% and 12.5% for the six months ended June 30, 2014 and 2013, respectively. The Company depends significantly upon its collaborations with Takeda and Abbott, and its revenues may be adversely impacted if these relationships are disrupted. Fair Value of Financial Instruments The carrying amounts of the Company’s financial instruments approximate their fair values based on their short maturities, independent valuations or internal assessments. The Company’s financial instruments include cash and cash equivalents, restricted cash, current and non-current investments, receivables, accounts payable and accrued expenses. The carrying amounts of the notes payable at June 30, 2014 and December 31, 2013 were less than the estimated fair values (see Note 9 below). Accounts Receivable and Unbilled Accounts Receivable The Company’s allowance for doubtful accounts related to certain disputed Takeda invoices totaled approximately $653,000 and $440,000 as of June 30, 2014 and December 31, 2013, respectively.

Note 3 - Net Income Per Share

6 Months Ended

Jun. 30, 2014

Earnings Per Share [Abstract]

Earnings Per Share [Text Block]

3. Net Income per Share

Basic net income per share is computed by dividing net income by the sum of the weighted average class A common shares outstanding. Diluted net income per share is computed by dividing net income by the weighted average common shares and potential dilutive common shares outstanding. Diluted net loss per share, when applicable, is computed by dividing net loss by the weighted average common shares outstanding without the impact of potential dilutive common shares outstanding because they would have an anti-dilutive impact on diluted net loss per share.

The computation of net income per share for the three and six months ended June 30, 2014 and 2013 is shown below:

	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands, except per share data)	2014		2013		2014		2013
Basic net income per share:
Net income	$	1,610	$	6,245	$	2,366	$	3,169

Weighted average class A common shares outstanding		43,640		41,604		43,521		41,533

Basic net income per share	$	0.04	$	0.15	$	0.05	$	0.08

Diluted net income per share:
Net income	$	1,610	$	6,245	$	2,366	$	3,169

Weighted average class A common shares outstanding		43,640		41,604		43,521		41,533
Assumed exercise of stock options under the treasury stock method		-		1,264		88		1,064
		43,640		42,868		43,609		42,597

Diluted net income per share	$	0.04	$	0.15	$	0.05	$	0.07

The following securities were excluded from the computation of diluted net income per share for the three and six months ended June 30, 2014 and 2013 as their effect would be anti-dilutive:

	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands)	2014		2013		2014		2013
Employee stock options		1,169		602		933		602

Note 4 - Current and Non-Current Investments

6 Months Ended

Jun. 30, 2014

Investments Schedule [Abstract]

Investment [Text Block]

4. Current and Non-Current Investments

At June 30, 2014 and December 31, 2013, current and non-current available-for-sale investments consisted of the following securities:

	June 30, 2014
(In thousands)	Cost		Unrealized Gains		Unrealized Losses			Fair Value
Current:
U.S. government securities	$	1,000	$	-	$	-		$	1,000
U.S. government agencies		9,515		2		-			9,517
Certificates of deposits		3,500		-		-			3,500
Corporate bonds		-		-		-			-
Total	$	14,015	$	2	$	-		$	14,017

Non-current:
U.S. government agencies	$	3,702	$	-	$	(10	)	$	3,692
Certificates of deposit		2,750		-		-			2,750
Corporate bonds		1,022		-		(4	)		1,018
Total	$	7,474	$	-	$	(14	)	$	7,460

	December 31, 2013
(In thousands)	Cost		Unrealized Gains		Unrealized Losses			Fair Value
Current:
U.S. government securities	$	1,000	$	-	$	-		$	1,000
U.S. government agencies		9,048		3		-			9,051
Certificates of deposit		3,500		-		-			3,500
Corporate bonds		752		-		-			752
Municipal securities		1,700		-		-			1,700
Total	$	16,000	$	3	$	-		$	16,003

Non-current:
U.S. government agencies	$	4,212	$	-	$	(3	)	$	4,209
Certificates of deposits		2,500		-		-			2,500
Corporate bonds		511		-		(1	)		510
Total	$	7,223	$	-	$	(4	)	$	7,219

The Company performs fair value measurements in accordance with the Financial Accounting Standards Board’s guidance for fair value measurements and disclosures, which defines fair value as the exchange price that would be received for selling an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. A fair value hierarchy is established which requires the Company to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The Company classifies its investments into the following categories based on the three levels of inputs used to measure fair value:

Level 1: quoted prices in active markets for identical assets or liabilities;

Level 2: inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; or

Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The Company’s assets measured at fair value on a recurring basis, including cash equivalents, which are subject to the fair value disclosure requirements, at June 30, 2014 and December 31, 2013, were as follows:

	Fair Value Measurements at Reporting Date Using

June 30, 2014 (In thousands)	Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
U.S. government securities	$	-	$	1,000	$	-	$	1,000
U.S. government agencies		-		13,208		-		13,208
U.S. commercial paper		-		7,949		-		7,949
Certificates of deposit		-		6,250		-		6,250
Corporate bonds		-		3,995		-		3,995
Money market funds		7,514		-		-		7,514
Total assets measured at fair value	$	7,514	$	32,402	$	-	$	39,916

	Fair Value Measurements at Reporting Date Using
December 31, 2013 (In thousands)	Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
U.S. government securities	$	-	$	1,000	$	-	$	1,000
U.S. government agencies		-		13,260		-		13,260
U.S. commercial paper		-		6,449		-		6,449
Municipal securities		-		1,700		-		1,700
Certificates of deposit		-		6,000		-		6,000
Corporate bonds		-		5,533		-		5,533
Money market funds		5,955		-		-		5,955
Total assets measured at fair value	$	5,955	$	33,942	$	-	$	39,897

If quoted prices in active markets for identical assets and liabilities are not available to determine fair value, then the Company uses quoted prices for similar assets and liabilities or inputs other than the quoted prices that are observable, either directly or indirectly. This pricing methodology applies to the Company’s Level 2 investments.

Note 5 - Intangible Assets	6 Months Ended
Note 5 - Intangible Assets	Jun. 30, 2014
Disclosure Text Block [Abstract]
Intangible Assets Disclosure [Text Block]	5. Intangible Assets In April 2009, the Company entered into an agreement with R-Tech Ueno, Ltd, or R-Tech, or the 2009 R-Tech Agreement, to license all patents and other intellectual property rights related to RESCULA for its U.S. Food and Drug Administration, or FDA, approved indication and any new indications for unoprostone isopropyl in the United States and Canada. A supplemental new drug application for RESCULA (unoprostone isopropyl ophthalmic solution) 0.15% for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension was approved by the FDA in December 2012 and the Company began commercializing the product in February 2013. Under the terms of the 2009 R-Tech Agreement, the Company has made upfront and milestone payments totaling $3.5 million and may be required to pay up to $5.0 million in additional milestone payments based on the achievement of specified development and commercialization goals. The Company allocated the acquisition cost between an intangible asset of $3.4 million and a non-current prepaid inventory of $85,000. The $3.4 million intangible asset is included in intangible assets, net in the accompanying Condensed Consolidated Balance Sheets as of June 30, 2014 and December 31, 2013. The non-current prepaid inventory of $85,000 was written-off during the quarter ended September 30, 2013. The cost of the intangible asset is being amortized over the 10-year life of the 2009 R-Tech Agreement, which the Company believes approximates the useful life of the underlying rights and data. Amortization expense was approximately $85,000 for each of the three months ended June 30, 2014 and 2013, and approximately $171,000 for each of the six months ended June 30, 2014 and 2013. The annual amortization expense will be approximately $341,000 through April 2019. The unamortized amount included in intangible assets was $1.6 million and $1.8 million at June 30, 2014 and December 31, 2013, respectively. In March 2011, the Company entered into a license agreement with R-Tech for unoprostone isopropyl, or the 2011 R-Tech Agreement, expanding the Company’s development and commercialization rights as well as its territories beyond their previously agreed territory of the United States and Canada to the rest of the world, with the exception of Japan, Korea, Taiwan and the People’s Republic of China. The Company is currently evaluating the opportunities to obtain an appropriate label in the European Union and other European countries, and the timing of seeking reauthorization in those countries to commercialize unoprostone isopropyl. Pursuant to the 2011 R-Tech Agreement, the Company has made payments to R-Tech of $6.0 million, which is reflected in intangible assets, net in the accompanying Condensed Consolidated Balance Sheets, and may be required to pay up to $100.0 million in additional milestone payments to R-Tech based on the achievement of specified development and commercialization goals. The Company will be responsible for all development, regulatory, and commercialization activities. The Company is amortizing the $6.0 million over the 10-year life of the 2011 R-Tech Agreement, which the Company believes approximates the useful life of the underlying rights and data. Amortization expense was approximately $153,000 for each of the three months ended June 30, 2014 and 2013, and approximately $307,000 for each of the six months ended June 30, 2014 and 2013. The annual amortization expense will be approximately $613,000 through March 2021. The unamortized amount included in intangible assets was $4.1 million and $4.4 million at June 30, 2014 and December 31, 2013, respectively. The Company reviews intangible assets for impairment when events or changes in circumstances indicate that the carrying value of its intangible assets may not be recoverable. Impairment in the carrying value of an intangible asset is recognized whenever anticipated future undiscounted cash flows from an intangible asset are estimated to be less than its carrying value. There have been no impairment charges recorded during the three months ended June 30, 2014 and 2013 since there have been no indicators of impairment during those periods. If the Company’s actual results, or the plans and estimates used in future impairment analyses, are lower than the original estimates used to assess the recoverability of these assets, the Company could incur future impairment charges.

Note 6 - Accrued Expenses

6 Months Ended

Jun. 30, 2014

Payables and Accruals [Abstract]

Accounts Payable and Accrued Liabilities Disclosure [Text Block]

6. Accrued Expenses

Accrued expenses consist of the following as of June 30, 2014 and December 31, 2013:

(In thousands)	June 30, 2014		December 31, 2013
Research and development costs	$	2,621	$	1,775
Employee compensation		1,778		2,531
Selling and marketing costs		310		584
Legal service fees		611		14
Other accrued expenses		944		778
Total	$	6,264	$	5,682

Note 7 - Commitments

6 Months Ended

Jun. 30, 2014

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies Disclosure [Text Block]

7. Commitments

Operating Leases

The Company leases office space in the United States, Switzerland and Japan under operating leases through 2018. Total future minimum, non-cancelable lease payments under operating leases are as follows as of June 30, 2014:

(In thousands of U.S. dollars)	June 30, 2014
2014	$	713
2015		1,275
2016		1,306
2017		361
2018		220
Total minimum lease payments	$	3,875

Rent expense for all operating leases was approximately $345,000 and $343,000 for the three months ended June 30, 2014 and 2013, respectively, and $696,000 and $693,000 for the six months ended June 30, 2014 and 2013, respectively.

Research and Development Costs

The Company routinely enters into agreements with third-party contract research organizations to oversee clinical research and development studies provided on an outsourced basis, and to assist in other research and development activities. The Company generally is not contractually obligated to pay the third party if the service or reports are not provided. Total future estimated costs under these agreements as of June 30, 2014 were approximately $6.5 million.

Numab Commitment

In the event that Numab defaults under its loan with Zurcher Kantonalbank, the Company’s maximum contingent liability under the Numab Agreement (see Note 8) is $2.5 million. As of June 30, 2014, the potential amount of payments in the event of Numab’s default was $2.2 million. At June 30, 2014 and December 31, 2013, the Company had a recorded liability of $949,000 and $663,000, respectively, to meet a potential loan default by Numab.

Note 8 - Related Party Transactions

6 Months Ended

Jun. 30, 2014

8. Related Party Transactions

R-Tech Ueno, Ltd.

The Company recorded the following expenses for the three and six months ended June 30, 2014 and 2013 under all of its agreements with R-Tech, including the 2009 R-Tech Agreement, the 2011 R-Tech Agreement and various exclusive supply agreements with R-Tech:

	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands)	2014		2013		2014		2013
Clinical supplies	$	65	$	26	$	166	$	220
Other research and development services		21		64		31		106
Commercial supplies		4,080		2,896		7,626		4,733
	$	4,166	$	2,986	$	7,823	$	5,059

The following table summarizes the amounts included in deferred revenue resulting from the deferral of upfront payments relating to the exclusive supply agreements with R-Tech as of June 30, 2014 and December 31, 2013:

(In thousands)	June 30, 2014		December 31, 2013
Deferred revenue, current	$	268	$	477
Deferred revenue, non-current		4,856		4,925
	$	5,124	$	5,402

The Company recognized approximately $104,000 of revenue relating to its agreements with R-Tech for each of the three months ended June 30, 2014 and 2013, and $268,000 for each of the six months ended June 30, 2014 and 2013. Such revenue was recorded as contract and collaboration revenue in the accompanying Condensed Consolidated Statements of Operations and Comprehensive Income.

On July 15, 2014, the Company received an approval letter from the FDA to its prior approval supplement, or PAS, in response to FDA’s review of the revised Drug Master File of R-Tech. The approval letter provides for the addition of Nitto Medic in Japan as a new production site for RESCULA. The Company has adequate supply of RESCULA to be able to supply the U.S. market into the first quarter of 2015.

Numab AG

In September 2011, the Company entered into a Loan Guarantee and Development Agreement, or the Numab Agreement, with Numab. On July 1, 2014, Numab became a related party of the Company as a result of the Company hiring as an executive officer an individual who holds an ownership interest in Numab. Under the terms of the Numab Agreement, the Company provided Numab with CHF 5.0 million as collateral and serves as guarantor for Numab on a loan from a third party, Zurcher Kantonalbank. During the first quarter of 2013, the collateral amount was reduced to CHF 2.2 million, or approximately $2.5 million as of June 30, 2014. As of June 30, 2014, Numab has utilized CHF 2.0 million of its loan facility, or approximately $2.2 million.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References + Details

Note 9 - Notes Payable

6 Months Ended

Jun. 30, 2014

Debt Disclosure [Abstract]

Debt Disclosure [Text Block]

9. Notes Payable

In November 2010, the Company entered into a secured term loan agreement with the Tokyo-Mitsubishi Bank for ¥1,000,000,000, approximating $11.6 million as of the closing date. The loan renews every November. The interest rate at June 30, 2014 was 1.21%. The outstanding loan balances included in the accompanying Condensed Consolidated Balance Sheets were $9.9 million and $9.5 million as of June 30, 2014 and December 31, 2013, respectively. A deposit of $14.9 million with the Tokyo-Mitsubishi Bank collateralizing the loan bears annual interest of 0.25%.

In March 2013, the Company entered into a secured term loan agreement with the Mizuho Bank for ¥1,000,000,000, approximating $10.6 million as of the closing date. The interest rate at June 30, 2014 was 0.46%. The loan renews every March. The outstanding loan balances included in the accompanying Condensed Consolidated Balance Sheets were $9.9 million and $9.5 million as of June 30, 2014 and December 31, 2013, respectively. A deposit of $11.0 million with the Mizuho Bank collateralizing the loan bears annual interest of 0.30%.

In connection with the Company’s acquisition of SAG in 2010, the Company issued a subordinated unsecured promissory note to each of the Ueno and Kuno Trusts. The interest rate beginning June 1, 2014 is 4.32%.

Due to changes in LIBOR rates, the Company has estimated the fair value of the notes payable as shown in the table below.

Notes payable at their fair value and carrying value consist of the following as of June 30, 2014 and December 31, 2013:

	Fair Value				Carrying Value
	June 30,		December 31,		June 30,		December 31,
(In thousands)	2014		2013		2014		2013
Loan agreements	$	19,724	$	19,008	$	19,724	$	19,008
Promissory notes, Sellers of SAG		30,984		34,889		29,807		33,712
	$	50,708	$	53,897	$	49,531	$	52,720

Notes payable, current					$	27,790	$	26,892
Notes payable, non-current						21,741		25,828
					$	49,531	$	52,720

The Company’s debt is subject to the fair value disclosure requirements as discussed in Note 4 above, and is classified as a Level 2 security.

Note 10 - Collaboration and License Agreements

6 Months Ended

Jun. 30, 2014

Collaborative And License Arrangement Disclosure [Abstract]

Collaborative And License Arrangement Disclosure [Text Block]

10. Collaboration and License Agreements

Abbott Agreement

The following table summarizes the cash streams and related revenue recognized or deferred under the Abbott Agreements for the six months ended June 30, 2014:

(In thousands)	Amount Deferred at December 31, 2013		Cash Received for the Six Months Ended June 30, 2014		Revenue Recognized for the Six Months Ended June 30, 2014		Change in Accounts Receivable for the Six Months Ended June 30, 2014		Foreign Currency Effects for the Six Months Ended June 30, 2014			Amount Deferred at June 30, 2014
Collaboration revenue:
Up-front payment associated with the Company's obligation to participate in joint committees	$	555	$	-	$	20	$	-	$	21		$	556

Product sales revenue:	$	-	$	12,219	$	13,300	$	1,213	$	(132	)	$	-

Takeda Agreements

The Company has received a total of $150.0 million in upfront and development milestone payments through June 30, 2014 under the Takeda Agreement. The Company is potentially entitled to receive additional development milestone and commercialization milestone payments under the Takeda Agreement, although there can be no assurance that the Company will receive any such payments.

The following table summarizes the cash streams and related revenue recognized or deferred under the Takeda Agreements for the six months ended June 30, 2014:

(In thousands)	Amount Deferred at December 31, 2013		Cash Received for the Six Months Ended June 30, 2014		Revenue Recognized for the Six Months Ended June 30, 2014			Change in Accounts Receivable for the Six Months Ended June 30, 2014*			Amount Deferred at June 30, 2014
Collaboration revenue:
Up-front payment associated with the Company's obligation to participate in joint committees	$	1,029	$	-	$	74	$	-		$	955

Research and development revenue:
Reimbursement of research and development expenses	$	419	$	5,765	$	3,484	$	(355	)	$	2,345

Product royalty revenue	$	-	$	28,330	$	27,389	$	(941	)		-

Co-promotion revenue	$	-	$	371	$	1,085	$	714			-

* Includes billed and unbilled accounts receivable.

Note 11 - Stock Option Plans

6 Months Ended

Jun. 30, 2014

Stockholders' Equity Note [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

11. Stock Option Plans

A summary of the employee stock option activity for the six months ended June 30, 2014 under the Company’s Amended and Restated 2001 Stock Incentive Plan, or the 2001 Stock Incentive Plan, is presented below:

	Shares		Weighted Average Exercise Price Per Share		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
Options outstanding, December 31, 2013		146,200	$	10.00
Options outstanding, June 30, 2014		146,200		10.00		1.53	$	-
Options exercisable, June 30, 2014		146,200		10.00		1.53	$	-

A summary of the employee stock option activity for the six months ended June 30, 2014 under the Company’s Amended and Restated 2006 Stock Incentive Plan is presented below:

	Shares			Weighted Average Exercise Price Per Share		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
Options outstanding, December 31, 2013		2,513,063		$	5.03
Options granted		870,000			8.07
Options exercised		(370,140	)		4.41
Options forfeited		(90,984	)		4.42
Options expired		(183,028	)		4.41
Options outstanding, June 30, 2014		2,738,911			6.14		7.81	$	3,940,531
Options exercisable, June 30, 2014		982,451			5.86		6.72	$	1,805,357

The weighted average grant date fair value of options granted during the six months ended June 30, 2014 and the year ended December 31, 2013 was $8.07 and $7.36, respectively. As of June 30, 2014, approximately $3.8 million of total unrecognized compensation costs, net of estimated forfeitures related to non-vested awards, are expected to be recognized over a weighted average period of 3.11 years.

A summary of the non-employee stock option activity for the six months ended June 30, 2014 under the Company’s 2001 Stock Incentive Plan is presented below:

	Shares			Weighted Average Exercise Price Per Share		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
Options outstanding, December 31, 2013		410,000		$	5.85
Options exercised		(67,500	)		5.85
Options outstanding, June 30, 2014		342,500			5.85		0.83	$	359,625
Options exercisable, June 30, 2014		342,500			5.85		0.83	$	359,625

Employee Stock Purchase Plan

Under the Company’s 2006 Employee Stock Purchase Plan, the Company received $7,839 and $6,126 upon the employees’ purchase of 1,196 and 980 shares of class A common stock during the three months ended June 30, 2014 and 2013, respectively, and $13,226 and $10,997 upon the employees’ purchase of 1,989 and 1,764 shares of class A common stock during the six months ended June 30, 2014 and 2013, respectively.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

Note 12 - Income Taxes	6 Months Ended
Note 12 - Income Taxes	Jun. 30, 2014
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	12. Income Taxes For the three months ended June 30, 2014 and 2013, the Company recorded tax provisions of $1.8 million and $4.3 million, respectively. For the six months ended June 30, 2014 and 2013, the Company recorded tax provisions of $3.1 million and $5.5 million, respectively. The tax provision for the three and six months ended June 30, 2014 primarily pertained to the pre-tax income and losses generated by the Company’s U.S., Japanese and Swiss subsidiaries. The tax provision for the three and six months ended June 30, 2013 primarily pertained to the pre-tax income generated by the Company’s U.S. and Japanese subsidiaries. The Company will continue to evaluate the need for a valuation allowance in foreign jurisdictions and may partially remove the valuation allowance of its foreign subsidiaries in 2014; any such release would have a positive impact on the results of operations. Uncertain Tax Positions The Company had an outstanding non-current income tax liability of approximately $971,000, including interest, for uncertain tax positions as of June 30, 2014. The amount represented the aggregate tax effect of differences between tax return positions and the amounts otherwise recognized in the Company’s Condensed Consolidated Financial Statements. As of June 30, 2014, $971,000 is reflected as other liabilities in the accompanying Condensed Consolidated Balance Sheets. The liability for uncertain tax positions as of June 30, 2014 mainly pertained to the Company’s interpretation of nexus in certain states related to revenue sourcing for state income tax purposes. During the three and six months ended June 30, 2014, the liability for income taxes has decreased approximately $81,000 and increased approximately $292,000, respectively. These changes in the liability are primarily related to the filing positions taken in various jurisdictions related to income tax nexus.

Note 13 - Segment Reporting

6 Months Ended

Jun. 30, 2014

Segment Reporting [Abstract]

Segment Reporting Disclosure [Text Block]

13. Segment Reporting

The following is a summary of financial information for the Company’s reportable geographic segments:

(In thousands)	Americas			Europe			Asia			Consolidated
Three Months Ended June 30, 2014
Research and development revenue	$	1,700		$	-		$	-		$	1,700
Product royalty revenue		13,888			-			-			13,888
Product sales revenue		223			99			7,221			7,543
Co-promotion revenue		723			-			-			723
Contract and collaboration revenue		141			64			10			215
Total revenues		16,675			163			7,231			24,069
Costs of goods sold		146			14			3,636			3,796
Research and development expenses		2,243			1,223			786			4,252
Depreciation and amortization		186			166			8			360
Other operating expenses		8,839			2,500			511			11,850
Income (loss) from operations		5,261			(3,740	)		2,290			3,811
Interest income		22			1			-			23
Interest expense		(352	)		-			(40	)		(392	)
Other non-operating expense, net		5			942			(1,000	)		(53	)
Income (loss) before income taxes	$	4,936		$	(2,797	)	$	1,250		$	3,389
Capital expenditures	$	4		$	2		$	2		$	8

Three Months Ended June 30, 2013
Research and development revenue	$	11,461		$	-		$	-		$	11,461
Product royalty revenue		12,000			-			-			12,000
Product sales revenue		106			12			3,281			3,399
Co-promotion revenue		-			-			-			-
Contract and collaboration revenue		142			10			11			163
Total revenues		23,709			22			3,292			27,023
Costs of goods sold		53			3			1,852			1,908
Research and development expenses		1,304			1,941			1,180			4,425
Depreciation and amortization		112			251			9			372
Other operating expenses		8,159			1,130			860			10,149
Income (loss) from operations		14,081			(3,303	)		(609	)		10,169
Interest income		20			2			1			23
Interest expense		-			(449	)		(44	)		(493	)
Other non-operating expense, net		1			(72	)		941			870
Income (loss) before income taxes	$	14,102		$	(3,822	)	$	289		$	10,569
Capital expenditures	$	17		$	3		$	-		$	20

(In thousands)	Americas			Europe			Asia			Consolidated
Six Months Ended June 30, 2014
Research and development revenue	$	3,484		$	-		$	-		$	3,484
Product royalty revenue		27,389			-			-			27,389
Product sales revenue		381			155			13,319			13,855
Co-promotion revenue		1,085			-			-			1,085
Contract and collaboration revenue		283			114			20			417
Total revenues		32,622			269			13,339			46,230
Cost of goods sold		296			39			6,854			7,189
Research and development expenses		4,832			2,635			1,920			9,387
Depreciation and amortization		374			332			15			721
Other operating expenses		16,680			4,734			979			22,393
Income (loss) from operations		10,440			(7,471	)		3,571			6,540
Interest income		43			4			33			80
Interest expense		(711	)		-			(81	)		(792	)
Other non-operating expense, net		2			990			(1,368	)		(376	)
Income (loss) before income taxes	$	9,774		$	(6,477	)	$	2,155		$	5,452
Capital expenditures	$	45		$	2		$	2		$	49

Six Months Ended June 30, 2013
Research and development revenue	$	14,261		$	-		$	-		$	14,261
Product royalty revenue		23,677			-			-			23,677
Product sales revenue		107			20			5,489			5,616
Co-promotion revenue		61			-			-			61
Contract and collaboration revenue		283			22			22			327
Total revenues		38,389			42			5,511			43,942
Cost of goods sold		76			8			3,106			3,190
Research and development expenses		2,586			4,612			2,856			10,054
Depreciation and amortization		234			501			18			753
Other operating expenses		18,476			1,728			2,180			22,384
Income (loss) from operations		17,017			(6,807	)		(2,649	)		7,561
Interest income		35			6			1			42
Interest expense		-			(909	)		(79	)		(988	)
Other non-operating expense, net		(15	)		(264	)		2,299			2,020
Income (loss) before income taxes	$	17,037		$	(7,974	)	$	(428	)	$	8,635
Capital expenditures	$	31		$	106		$	3		$	140


As of June 30, 2014
Property and equipment, net	$	711		$	99		$	169		$	979
Identifiable assets, net of intercompany loans and investments	$	106,622		$	17,855		$	17,762		$	142,239

As of December 31, 2013
Property and equipment, net	$	869		$	112		$	175		$	1,156
Identifiable assets, net of intercompany loans and investments	$	95,350		$	23,843		$	17,684		$	136,877

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

+ Details

Note 14 - Subsequent Events	6 Months Ended
Note 14 - Subsequent Events	Jun. 30, 2014
Subsequent Events [Abstract]
Subsequent Events [Text Block]	14. Subsequent Events On July 14, 2014, Abbott announced that it had entered into a definitive agreement with Mylan Inc., or Mylan, whereby Mylan will acquire Abbott's non-U.S. developed markets specialty and branded generics business in an all-stock transaction, which includes a portfolio of more than 100 specialty and branded generic pharmaceutical products in five major therapeutic areas (cardio/metabolic, gastrointestinal, anti-infective/respiratory, CNS/pain and women's and men's health) and several patent-protected, novel and/or hard-to-manufacture products. The Company believes that the Abbott Agreement is one of the assets that Abbott is selling as part of this transaction. The Company expects to have discussions with Mylan about its performance of the Abbott Agreement and does not anticipate any adverse impact to sales of AMITIZA in Japan. On July 15, 2014, the Company received an approval letter to its PAS in response to FDA’s review of the revised Drug Master File of R-Tech. The approval letter provides for the addition of Nitto Medic in Japan as a new production site for RESCULA. The Company has adequate supply of RESCULA to be able to supply the U.S. market into the first quarter of 2015. Scottish Medicines Consortium, or SMC, has advised us that in their final guidance that will be issued on August 11, 2014, that AMITIZA is not recommended for use with NHS Scotland. We intend to explore available options to address this guidance.

Accounting Policies, by Policy (Policies)	6 Months Ended
Accounting Policies, by Policy (Policies)	Jun. 30, 2014
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America, or GAAP, and the rules and regulations of the Securities and Exchange Commission, or SEC, for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the Company’s Consolidated Financial Statements as of and for the year ended December 31, 2013 included in the Company’s Annual Report on Form 10-K, which was filed with the SEC on March 12, 2014. The financial information as of June 30, 2014 and for the three and six months ended June 30, 2014 and June 30, 2013 is unaudited. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. In the opinion of the Company’s management, all adjustments, consisting only of normal recurring adjustments or accruals, considered necessary for a fair statement of the results of these interim periods have been included. The results of the Company’s operations for any interim period are not necessarily indicative of the results that may be expected for any other interim period or for a full fiscal year. The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries: Sucampo AG, or SAG, based in Zug, Switzerland, through which the Company conducts certain of its worldwide and European operations; Sucampo Pharma, Ltd., based in Tokyo and Osaka, Japan, through which the Company conducts its Asian operations; Sucampo Pharma Americas LLC, based in Bethesda, Maryland, through which the Company conducts its North and South American operations; and Sucampo Pharma Europe, Ltd., based in Oxford, United Kingdom. The Company liquidated Ambrent Investments S.à r.l., based in Luxembourg, at the end of 2013. All significant inter-company balances and transactions have been eliminated. The preparation of financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]	Restricted Cash Restricted cash primarily represents collateral pledged to support a loan agreement with The Bank of Tokyo-Mitsubishi UFJ, Ltd., or the Tokyo-Mitsubishi Bank; a loan agreement with The Mizuho Bank, Ltd., or the Mizuho Bank; a loan agreement between Numab AG, or Numab, and Zurcher Kantonalbank, under which the Company serves as guarantor; and operating leases with certain financial institutions. Restricted cash totaled approximately $28.6 million at both June 30, 2014 and December 31, 2013.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Certain Risks, Concentrations and Uncertainties Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash and cash equivalents, restricted cash, investments and receivables. The Company places its cash, cash equivalents and restricted cash with highly rated financial institutions and invests its excess cash in highly rated investments. As of June 30, 2014 and December 31, 2013, approximately $21.7 million, or 20.9%, and $16.4 million, or 17.1%, respectively, of the Company’s cash, cash equivalents, restricted cash and investments were issued or insured by the United States government or United States government agencies. The Company has not experienced any losses on these accounts related to amounts in excess of insured limits. Revenues from Takeda, an unrelated party, accounted for 68.1% and 87.3% of the Company’s total revenues for the three months ended June 30, 2014 and 2013, respectively, and 69.6% and 87.1% for the six months ended June 30, 2014 and 2013, respectively. Accounts receivable, unbilled accounts receivable and product royalties receivable from Takeda accounted for 80.8% and 88.2% of the Company’s total accounts receivable, unbilled accounts receivable and product royalties receivable at June 30, 2014 and December 31, 2013, respectively. Revenues from another unrelated party, Abbott, accounted for 30.0% and 12.1% of the Company’s total revenues for the three months ended June 30, 2014 and 2013, respectively, and 28.8% and 12.5% for the six months ended June 30, 2014 and 2013, respectively. The Company depends significantly upon its collaborations with Takeda and Abbott, and its revenues may be adversely impacted if these relationships are disrupted.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments The carrying amounts of the Company’s financial instruments approximate their fair values based on their short maturities, independent valuations or internal assessments. The Company’s financial instruments include cash and cash equivalents, restricted cash, current and non-current investments, receivables, accounts payable and accrued expenses. The carrying amounts of the notes payable at June 30, 2014 and December 31, 2013 were less than the estimated fair values (see Note 9 below).
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Accounts Receivable and Unbilled Accounts Receivable The Company’s allowance for doubtful accounts related to certain disputed Takeda invoices totaled approximately $653,000 and $440,000 as of June 30, 2014 and December 31, 2013, respectively.

- Definition

Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.

+ References + Details

Note 1 - Business Organization and Basis of Presentation (Tables)

6 Months Ended

Jun. 30, 2014

Disclosure Text Block [Abstract]

Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]

	Presentation as of three months ended June 30, 2013
(In thousands, except per share data)	As Previously Reported			Revision Adjustment			As Revised
Gross profit	$	25,115		$	(25,115	)	$	-
Total costs and expenses		(14,946	)		(1,908	)		(16,854	)
Other income (expense), net		744			126			870
Total non-operating income (expense), net		274			126			400
Income (loss) before income taxes		10,443			126			10,569
Net income		6,119			126			6,245
Net income per share: Diluted		0.14			0.01			0.15
Comprehensive income		5,914			126			6,040

	Presentation as of six months ended June 30, 2013
(In thousands, except per share data)	As Previously Reported			Revision Adjustment			As Revised
Gross profit	$	40,752		$	(40,752	)	$	-
Total costs and expenses		(33,191	)		(3,190	)		(36,381	)
Other income (expense), net		1,825			195			2,020
Total non-operating income (expense), net		879			195			1,074
Income (loss) before income taxes		8,440			195			8,635
Net income		2,974			195			3,169
Net income per share: Basic		0.07			0.01			0.08
Comprehensive income		2,806			195			3,001

Net cash provided by (used in) operating activities		(5,902	)		1,298			(4,604	)
Net cash provided by (used in) investing activities		(7,506	)		466			(7,040	)
Effect of exchange rates on cash and cash equivalents		267			(1,764	)		(1,497	)

	Presentation as of December 31, 2013
(In thousands)	As Previously Reported			Revision Adjustment			As Revised
Other assets	$	584		$	(96	)	$	488
Total assets		136,973			(96	)		136,877
Other liabilities		2,150			(917	)		1,233
Total liabilities		78,825			(917	)		77,908
Accumulated deficit		(27,681	)		821			(26,860	)
Total stockholders' equity		58,148			821			58,969

Note 3 - Net Income Per Share (Tables)

6 Months Ended

Jun. 30, 2014

Earnings Per Share [Abstract]

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands, except per share data)	2014		2013		2014		2013
Basic net income per share:
Net income	$	1,610	$	6,245	$	2,366	$	3,169

Weighted average class A common shares outstanding		43,640		41,604		43,521		41,533

Basic net income per share	$	0.04	$	0.15	$	0.05	$	0.08

Diluted net income per share:
Net income	$	1,610	$	6,245	$	2,366	$	3,169

Weighted average class A common shares outstanding		43,640		41,604		43,521		41,533
Assumed exercise of stock options under the treasury stock method		-		1,264		88		1,064
		43,640		42,868		43,609		42,597

Diluted net income per share	$	0.04	$	0.15	$	0.05	$	0.07

Schedule of Potentially Dilutive Securities [Table Text Block]

	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands)	2014		2013		2014		2013
Employee stock options		1,169		602		933		602

Note 4 - Current and Non-Current Investments (Tables)

6 Months Ended

Jun. 30, 2014

Investments Schedule [Abstract]

Available-for-sale Securities [Table Text Block]

	June 30, 2014
(In thousands)	Cost		Unrealized Gains		Unrealized Losses			Fair Value
Current:
U.S. government securities	$	1,000	$	-	$	-		$	1,000
U.S. government agencies		9,515		2		-			9,517
Certificates of deposits		3,500		-		-			3,500
Corporate bonds		-		-		-			-
Total	$	14,015	$	2	$	-		$	14,017

Non-current:
U.S. government agencies	$	3,702	$	-	$	(10	)	$	3,692
Certificates of deposit		2,750		-		-			2,750
Corporate bonds		1,022		-		(4	)		1,018
Total	$	7,474	$	-	$	(14	)	$	7,460

	December 31, 2013
(In thousands)	Cost		Unrealized Gains		Unrealized Losses			Fair Value
Current:
U.S. government securities	$	1,000	$	-	$	-		$	1,000
U.S. government agencies		9,048		3		-			9,051
Certificates of deposit		3,500		-		-			3,500
Corporate bonds		752		-		-			752
Municipal securities		1,700		-		-			1,700
Total	$	16,000	$	3	$	-		$	16,003

Non-current:
U.S. government agencies	$	4,212	$	-	$	(3	)	$	4,209
Certificates of deposits		2,500		-		-			2,500
Corporate bonds		511		-		(1	)		510
Total	$	7,223	$	-	$	(4	)	$	7,219

Fair Value, Assets Measured on Recurring Basis [Table Text Block]

	Fair Value Measurements at Reporting Date Using

June 30, 2014 (In thousands)	Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
U.S. government securities	$	-	$	1,000	$	-	$	1,000
U.S. government agencies		-		13,208		-		13,208
U.S. commercial paper		-		7,949		-		7,949
Certificates of deposit		-		6,250		-		6,250
Corporate bonds		-		3,995		-		3,995
Money market funds		7,514		-		-		7,514
Total assets measured at fair value	$	7,514	$	32,402	$	-	$	39,916

	Fair Value Measurements at Reporting Date Using
December 31, 2013 (In thousands)	Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
U.S. government securities	$	-	$	1,000	$	-	$	1,000
U.S. government agencies		-		13,260		-		13,260
U.S. commercial paper		-		6,449		-		6,449
Municipal securities		-		1,700		-		1,700
Certificates of deposit		-		6,000		-		6,000
Corporate bonds		-		5,533		-		5,533
Money market funds		5,955		-		-		5,955
Total assets measured at fair value	$	5,955	$	33,942	$	-	$	39,897

- Definition

Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.

+ References + Details

Note 6 - Accrued Expenses (Tables)

6 Months Ended

Jun. 30, 2014

Payables and Accruals [Abstract]

Schedule of Accrued Liabilities [Table Text Block]

(In thousands)	June 30, 2014		December 31, 2013
Research and development costs	$	2,621	$	1,775
Employee compensation		1,778		2,531
Selling and marketing costs		310		584
Legal service fees		611		14
Other accrued expenses		944		778
Total	$	6,264	$	5,682

Note 7 - Commitments (Tables)

6 Months Ended

Jun. 30, 2014

Commitments and Contingencies Disclosure [Abstract]

Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]

(In thousands of U.S. dollars)	June 30, 2014
2014	$	713
2015		1,275
2016		1,306
2017		361
2018		220
Total minimum lease payments	$	3,875

Note 8 - Related Party Transactions (Tables)

6 Months Ended

Jun. 30, 2014

Deferred Revenue [Member]

(In thousands)	June 30, 2014		December 31, 2013
Deferred revenue, current	$	268	$	477
Deferred revenue, non-current		4,856		4,925
	$	5,124	$	5,402

	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands)	2014		2013		2014		2013
Clinical supplies	$	65	$	26	$	166	$	220
Other research and development services		21		64		31		106
Commercial supplies		4,080		2,896		7,626		4,733
	$	4,166	$	2,986	$	7,823	$	5,059

Note 9 - Notes Payable (Tables)

6 Months Ended

Jun. 30, 2014

Debt Disclosure [Abstract]

Schedule of Debt [Table Text Block]

	Fair Value				Carrying Value
	June 30,		December 31,		June 30,		December 31,
(In thousands)	2014		2013		2014		2013
Loan agreements	$	19,724	$	19,008	$	19,724	$	19,008
Promissory notes, Sellers of SAG		30,984		34,889		29,807		33,712
	$	50,708	$	53,897	$	49,531	$	52,720

Notes payable, current					$	27,790	$	26,892
Notes payable, non-current						21,741		25,828
					$	49,531	$	52,720

Note 10 - Collaboration and License Agreements (Tables)

6 Months Ended

Jun. 30, 2014

Abbott [Member]

Note 10 - Collaboration and License Agreements (Tables) [Line Items]

Deferred Revenue, by Arrangement, Disclosure [Table Text Block]

(In thousands)	Amount Deferred at December 31, 2013		Cash Received for the Six Months Ended June 30, 2014		Revenue Recognized for the Six Months Ended June 30, 2014		Change in Accounts Receivable for the Six Months Ended June 30, 2014		Foreign Currency Effects for the Six Months Ended June 30, 2014			Amount Deferred at June 30, 2014
Collaboration revenue:
Up-front payment associated with the Company's obligation to participate in joint committees	$	555	$	-	$	20	$	-	$	21		$	556

Product sales revenue:	$	-	$	12,219	$	13,300	$	1,213	$	(132	)	$	-

Takeda [Member]

Note 10 - Collaboration and License Agreements (Tables) [Line Items]

Deferred Revenue, by Arrangement, Disclosure [Table Text Block]

(In thousands)	Amount Deferred at December 31, 2013		Cash Received for the Six Months Ended June 30, 2014		Revenue Recognized for the Six Months Ended June 30, 2014			Change in Accounts Receivable for the Six Months Ended June 30, 2014*			Amount Deferred at June 30, 2014
Collaboration revenue:
Up-front payment associated with the Company's obligation to participate in joint committees	$	1,029	$	-	$	74	$	-		$	955

Research and development revenue:
Reimbursement of research and development expenses	$	419	$	5,765	$	3,484	$	(355	)	$	2,345

Product royalty revenue	$	-	$	28,330	$	27,389	$	(941	)		-

Co-promotion revenue	$	-	$	371	$	1,085	$	714			-

Note 11 - Stock Option Plans (Tables)

6 Months Ended

Jun. 30, 2014

Stockholders' Equity Note [Abstract]

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

	Shares		Weighted Average Exercise Price Per Share		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
Options outstanding, December 31, 2013		146,200	$	10.00
Options outstanding, June 30, 2014		146,200		10.00		1.53	$	-
Options exercisable, June 30, 2014		146,200		10.00		1.53	$	-

	Shares			Weighted Average Exercise Price Per Share		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
Options outstanding, December 31, 2013		2,513,063		$	5.03
Options granted		870,000			8.07
Options exercised		(370,140	)		4.41
Options forfeited		(90,984	)		4.42
Options expired		(183,028	)		4.41
Options outstanding, June 30, 2014		2,738,911			6.14		7.81	$	3,940,531
Options exercisable, June 30, 2014		982,451			5.86		6.72	$	1,805,357

	Shares			Weighted Average Exercise Price Per Share		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
Options outstanding, December 31, 2013		410,000		$	5.85
Options exercised		(67,500	)		5.85
Options outstanding, June 30, 2014		342,500			5.85		0.83	$	359,625
Options exercisable, June 30, 2014		342,500			5.85		0.83	$	359,625

Note 13 - Segment Reporting (Tables)

6 Months Ended

Jun. 30, 2014

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment [Table Text Block]

(In thousands)	Americas			Europe			Asia			Consolidated
Three Months Ended June 30, 2014
Research and development revenue	$	1,700		$	-		$	-		$	1,700
Product royalty revenue		13,888			-			-			13,888
Product sales revenue		223			99			7,221			7,543
Co-promotion revenue		723			-			-			723
Contract and collaboration revenue		141			64			10			215
Total revenues		16,675			163			7,231			24,069
Costs of goods sold		146			14			3,636			3,796
Research and development expenses		2,243			1,223			786			4,252
Depreciation and amortization		186			166			8			360
Other operating expenses		8,839			2,500			511			11,850
Income (loss) from operations		5,261			(3,740	)		2,290			3,811
Interest income		22			1			-			23
Interest expense		(352	)		-			(40	)		(392	)
Other non-operating expense, net		5			942			(1,000	)		(53	)
Income (loss) before income taxes	$	4,936		$	(2,797	)	$	1,250		$	3,389
Capital expenditures	$	4		$	2		$	2		$	8

Three Months Ended June 30, 2013
Research and development revenue	$	11,461		$	-		$	-		$	11,461
Product royalty revenue		12,000			-			-			12,000
Product sales revenue		106			12			3,281			3,399
Co-promotion revenue		-			-			-			-
Contract and collaboration revenue		142			10			11			163
Total revenues		23,709			22			3,292			27,023
Costs of goods sold		53			3			1,852			1,908
Research and development expenses		1,304			1,941			1,180			4,425
Depreciation and amortization		112			251			9			372
Other operating expenses		8,159			1,130			860			10,149
Income (loss) from operations		14,081			(3,303	)		(609	)		10,169
Interest income		20			2			1			23
Interest expense		-			(449	)		(44	)		(493	)
Other non-operating expense, net		1			(72	)		941			870
Income (loss) before income taxes	$	14,102		$	(3,822	)	$	289		$	10,569
Capital expenditures	$	17		$	3		$	-		$	20

(In thousands)	Americas			Europe			Asia			Consolidated
Six Months Ended June 30, 2014
Research and development revenue	$	3,484		$	-		$	-		$	3,484
Product royalty revenue		27,389			-			-			27,389
Product sales revenue		381			155			13,319			13,855
Co-promotion revenue		1,085			-			-			1,085
Contract and collaboration revenue		283			114			20			417
Total revenues		32,622			269			13,339			46,230
Cost of goods sold		296			39			6,854			7,189
Research and development expenses		4,832			2,635			1,920			9,387
Depreciation and amortization		374			332			15			721
Other operating expenses		16,680			4,734			979			22,393
Income (loss) from operations		10,440			(7,471	)		3,571			6,540
Interest income		43			4			33			80
Interest expense		(711	)		-			(81	)		(792	)
Other non-operating expense, net		2			990			(1,368	)		(376	)
Income (loss) before income taxes	$	9,774		$	(6,477	)	$	2,155		$	5,452
Capital expenditures	$	45		$	2		$	2		$	49

Six Months Ended June 30, 2013
Research and development revenue	$	14,261		$	-		$	-		$	14,261
Product royalty revenue		23,677			-			-			23,677
Product sales revenue		107			20			5,489			5,616
Co-promotion revenue		61			-			-			61
Contract and collaboration revenue		283			22			22			327
Total revenues		38,389			42			5,511			43,942
Cost of goods sold		76			8			3,106			3,190
Research and development expenses		2,586			4,612			2,856			10,054
Depreciation and amortization		234			501			18			753
Other operating expenses		18,476			1,728			2,180			22,384
Income (loss) from operations		17,017			(6,807	)		(2,649	)		7,561
Interest income		35			6			1			42
Interest expense		-			(909	)		(79	)		(988	)
Other non-operating expense, net		(15	)		(264	)		2,299			2,020
Income (loss) before income taxes	$	17,037		$	(7,974	)	$	(428	)	$	8,635
Capital expenditures	$	31		$	106		$	3		$	140


As of June 30, 2014
Property and equipment, net	$	711		$	99		$	169		$	979
Identifiable assets, net of intercompany loans and investments	$	106,622		$	17,855		$	17,762		$	142,239

As of December 31, 2013
Property and equipment, net	$	869		$	112		$	175		$	1,156
Identifiable assets, net of intercompany loans and investments	$	95,350		$	23,843		$	17,684		$	136,877

Note 1 - Business Organization and Basis of Presentation (Details)	Jun. 30, 2014
Disclosure Text Block [Abstract]
Number of products in clinical development	2

Note 1 - Business Organization and Basis of Presentation (Details) - Revision to Previously Issued Financial Statements - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Scenario, Previously Reported [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Gross profit		$ 25,115		$ 40,752
Total costs and expenses		(14,946)		(33,191)
Other income (expense), net		744		1,825
Total non-operating income (expense), net		274		879
Income (loss) before income taxes		10,443		8,440
Net income		$ 6,119		$ 2,974
Net income per share: Basic (in Dollars per share)				$ 0.07
Net income per share: Diluted (in Dollars per share)		$ 0.14
Comprehensive income		$ 5,914		$ 2,806
Net cash provided by (used in) operating activities				(5,902)
Net cash provided by (used in) investing activities				(7,506)
Effect of exchange rates on cash and cash equivalents				267
Other assets					$ 584
Total assets					136,973
Other liabilities					2,150
Total liabilities					78,825
Accumulated deficit					(27,681)
Total stockholders' equity					58,148
Restatement Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Gross profit		(25,115)		(40,752)
Total costs and expenses		(1,908)		(3,190)
Other income (expense), net		126		195
Total non-operating income (expense), net		126		195
Income (loss) before income taxes		126		195
Net income		$ 126		$ 195
Net income per share: Basic (in Dollars per share)				$ 0.01
Net income per share: Diluted (in Dollars per share)		$ 0.01
Comprehensive income		$ 126		$ 195
Net cash provided by (used in) operating activities				1,298
Net cash provided by (used in) investing activities				466
Effect of exchange rates on cash and cash equivalents				(1,764)
Other assets					(96)
Total assets					(96)
Other liabilities					(917)
Total liabilities					(917)
Accumulated deficit					821
Total stockholders' equity					821
Total costs and expenses	$ (20,258)	(16,854)	$ (39,690)	(36,381)
Other income (expense), net	(53)	870	(376)	2,020
Total non-operating income (expense), net	(422)	400	(1,088)	1,074
Income (loss) before income taxes	3,389	10,569	5,452	8,635
Net income	$ 1,610	$ 6,245	$ 2,366	$ 3,169
Net income per share: Basic (in Dollars per share)	$ 0.04	$ 0.15	$ 0.05	$ 0.08
Net income per share: Diluted (in Dollars per share)	$ 0.04	$ 0.15	$ 0.05	$ 0.07
Comprehensive income	$ 1,481	$ 6,040	$ 2,126	$ 3,001
Net cash provided by (used in) operating activities			4,095	(4,604)
Net cash provided by (used in) investing activities			1,636	(7,040)
Effect of exchange rates on cash and cash equivalents			159	$ (1,497)
Other assets	552		552		488
Total assets	142,239		142,239		136,877
Other liabilities	1,559		1,559		1,233
Total liabilities	72,866		72,866		77,908
Accumulated deficit	(24,494)		(24,494)		(26,860)
Total stockholders' equity	$ 69,373		$ 69,373		$ 58,969

Note 2 - Summary of Significant Accounting Policies (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Takeda [Member] \| Sales Revenue, Goods, Net [Member] \| Customer Concentration Risk [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Concentration Risk, Percentage	68.10%	87.30%	69.60%	87.10%
Takeda [Member] \| Accounts Receivable, Unbilled Accounts Receivable and Product Royalties Receivable [Member] \| Customer Concentration Risk [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Concentration Risk, Percentage			80.80%		88.20%
Abbott [Member] \| Sales Revenue, Goods, Net [Member] \| Customer Concentration Risk [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Concentration Risk, Percentage	30.00%	12.10%	28.80%	12.50%
Restricted Cash and Cash Equivalents (in Dollars)	$ 28,600,000		$ 28,600,000		$ 28,600,000
Cash, FDIC Insured Amount (in Dollars)	$ 21,700,000		$ 21,700,000		$ 16,400,000
PercentageOfDepositWithinFederallyInsuredLimits	20.90%		20.90%		17.10%
Allowance for Doubtful Accounts Receivable (in Dollars)	$ 653,000	$ 440,000	$ 653,000	$ 440,000

Note 3 - Net Income Per Share (Details) - Net Income (Loss) per Share - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Basic net income per share:
Net income (in Dollars)	$ 1,610	$ 6,245	$ 2,366	$ 3,169
Weighted average class A common shares outstanding	43,640	41,604	43,521	41,533
Assumed exercise of stock options under the treasury stock method		1,264	88	1,064
	43,640	42,868	43,609	42,597
Diluted net income per share (in Dollars per share)	$ 0.04	$ 0.15	$ 0.05	$ 0.07
Basic net income per share (in Dollars per share)	$ 0.04	$ 0.15	$ 0.05	$ 0.08

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Note 3 - Net Income Per Share (Details) - Potentially Dilutive Securities - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Employee Stock Option [Member]
Note 3 - Net Income Per Share (Details) - Potentially Dilutive Securities [Line Items]
Employee stock options	1,169	602	933	602
Employee stock options		1,264	88	1,064

Note 4 - Current and Non-Current Investments (Details) - Current and Non-Current Investments - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2014	Dec. 31, 2013
US Treasury and Government [Member] \| Current [Member]
Current:
Cost	$ 1,000	$ 1,000
Fair value	1,000	1,000
US Treasury and Government [Member] \| Non-current [Member]
Current:
Cost	3,702	4,212
Unrealized losses	(10)	(3)
Fair value	3,692	4,209
US Government Agencies Debt Securities [Member] \| Current [Member]
Current:
Cost	9,515	9,048
Unrealized gains	2	3
Fair value	9,517	9,051
Certificates of Deposit [Member] \| Current [Member]
Current:
Cost	3,500	3,500
Fair value	3,500	3,500
Certificates of Deposit [Member] \| Non-current [Member]
Current:
Cost	2,750	2,500
Fair value	2,750	2,500
Corporate Bond Securities [Member] \| Current [Member]
Current:
Cost		752
Fair value		752
Corporate Bond Securities [Member] \| Non-current [Member]
Current:
Cost	1,022	511
Unrealized losses	(4)	(1)
Fair value	$ 1,018	510
Municipal Bonds [Member] \| Current [Member]
Current:
Cost		1,700
Fair value		$ 1,700

Note 5 - Intangible Assets (Details) - USD ($)	1 Months Ended	3 Months Ended		4 Months Ended	6 Months Ended		12 Months Ended
Note 5 - Intangible Assets (Details) - USD ($)	Apr. 30, 2009	Jun. 30, 2014	Jun. 30, 2013	Apr. 30, 2009	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Non-current Prepaid Inventory [Member] \| 2009 R-Tech Agreement [Member]
Note 5 - Intangible Assets (Details) [Line Items]
Payments to Acquire Other Productive Assets				$ 85,000
Asset Impairment Charges							$ 85,000
Other Noncurrent Assets [Member] \| 2009 R-Tech Agreement [Member]
Note 5 - Intangible Assets (Details) [Line Items]
Finite-lived Intangible Assets Acquired					$ 3,400,000		3,400,000
Other Noncurrent Assets [Member] \| 2009 R-Tech Agreement [Member]
Note 5 - Intangible Assets (Details) [Line Items]
Finite-lived Intangible Assets Acquired				3,400,000
2009 R-Tech Agreement [Member]
Note 5 - Intangible Assets (Details) [Line Items]
Payments to Acquire Intangible Assets	$ 3,500,000
MilestonePaymentsMaximumAmount	$ 5,000,000			$ 5,000,000
Finite-Lived Intangible Asset, Useful Life					10 years
Amortization of Intangible Assets		$ 85,000	$ 85,000		$ 171,000	$ 171,000
Finite-Lived Intangible Assets, Annual Amortization Expense					341,000
Finite-Lived Intangible Assets, Net		1,600,000			1,600,000		1,800,000
2011 R-Tech Agreement [Member]
Note 5 - Intangible Assets (Details) [Line Items]
Payments to Acquire Intangible Assets					6,000,000
MilestonePaymentsMaximumAmount		100,000,000			100,000,000
Finite-lived Intangible Assets Acquired					$ 6,000,000
Finite-Lived Intangible Asset, Useful Life					10 years
Amortization of Intangible Assets		153,000	153,000		$ 307,000	$ 307,000
Finite-Lived Intangible Assets, Annual Amortization Expense					613,000
Finite-Lived Intangible Assets, Net		4,100,000			$ 4,100,000		$ 4,400,000
Asset Impairment Charges		$ 0	$ 0

Note 6 - Accrued Expenses (Details) - Accrued Expenses - USD ($) $ in Thousands	Jun. 30, 2014	Dec. 31, 2013
Accrued Expenses [Abstract]
Research and development costs	$ 2,621	$ 1,775
Employee compensation	1,778	2,531
Selling and marketing costs	310	584
Legal service fees	611	14
Other accrued expenses	944	778
Total	$ 6,264	$ 5,682

Note 7 - Commitments (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
Note 7 - Commitments (Details) - USD ($)	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Guarantee of Indebtedness of Others [Member]
Note 7 - Commitments (Details) [Line Items]
Loss Contingency, Range of Possible Loss, Maximum	$ 2,500,000		$ 2,500,000
Loss Contingency, Estimate of Possible Loss	2,200,000		2,200,000
Loss Contingency Accrual, Provision			949,000		$ 663,000
Operating Leases, Rent Expense	$ 345,000	$ 343,000	696,000	$ 693,000
Future Estimated Research and Development Costs			$ 6,500,000

Note 7 - Commitments (Details) - Future Minimum, Non-Cancelable Lease Payments $ in Thousands	Jun. 30, 2014 USD ($)
Future Minimum, Non-Cancelable Lease Payments [Abstract]
2014	$ 713
2015	1,275
2016	1,306
2017	361
2018	220
Total minimum lease payments	$ 3,875

Note 8 - Related Party Transactions (Details) SFr in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2014 USD ($)	Jun. 30, 2013 USD ($)	Jun. 30, 2014 USD ($)	Jun. 30, 2013 USD ($)	Jun. 30, 2014 CHF (SFr)	Sep. 30, 2011 CHF (SFr)
R-Tech [Member]
Note 8 - Related Party Transactions (Details) [Line Items]
Contracts Revenue \| $	$ 104,000	$ 104,000	$ 268,000	$ 268,000
Numab [Member]
Note 8 - Related Party Transactions (Details) [Line Items]
Long-term Debt, Gross	2,200,000		2,200,000		SFr 2.0
Numab Agreement [Member] \| Zurcher Kantonalbank [Member]
Note 8 - Related Party Transactions (Details) [Line Items]
Loans Pledged as Collateral \| SFr						SFr 5.0
Numab Agreement [Member]
Note 8 - Related Party Transactions (Details) [Line Items]
Loans Pledged as Collateral	$ 2,500,000		$ 2,500,000		SFr 2.2

Note 8 - Related Party Transactions (Details) - Expenses under Agreements with R-Tech - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Clinical Supplies [Member]
Related Party Transaction [Line Items]
Expenses related to R-Tech	$ 65	$ 26	$ 166	$ 220
Other research and development services [Member]
Related Party Transaction [Line Items]
Expenses related to R-Tech	21	64	31	106
Commercial supplies [Member]
Related Party Transaction [Line Items]
Expenses related to R-Tech	4,080	2,896	7,626	4,733
Expenses related to R-Tech	$ 4,166	$ 2,986	$ 7,823	$ 5,059

Note 8 - Related Party Transactions (Details) - Amounts Included in Deferred Revenue Resulting from Deferral of Upfront Payments Relating to Exclusive Supply Agreements with R-Tech - USD ($) $ in Thousands	Jun. 30, 2014	Dec. 31, 2013
R-Tech [Member]
Related Party Transaction [Line Items]
Deferred revenue, current	$ 268	$ 477
Deferred revenue, non-current	4,856	4,925
	5,124	5,402
Deferred revenue, current	1,794	1,365
Deferred revenue, non-current	$ 5,824	$ 6,169

Note 9 - Notes Payable (Details) $ in Millions	6 Months Ended
Note 9 - Notes Payable (Details) $ in Millions	Jun. 30, 2014 USD ($)	Dec. 31, 2013 USD ($)	Mar. 31, 2013 USD ($)	Mar. 31, 2013 JPY (¥)	Nov. 30, 2010 USD ($)	Nov. 30, 2010 JPY (¥)
Kuno and Ueno Trust [Member] \| Subordinated Unsecured Promissory Notes [Member]
Note 9 - Notes Payable (Details) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	4.32%
Secured Debt [Member] \| Tokyo-Mitsubishi Bank [Member]
Note 9 - Notes Payable (Details) [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity					$ 11.6	¥ 1,000,000,000
Line of Credit Facility, Interest Rate at Period End	1.21%
Long-term Line of Credit	$ 9.9	$ 9.5
Interest-bearing Deposits in Banks and Other Financial Institutions	$ 14.9
Weighted Average Rate Domestic Deposit	0.25%
Secured Debt [Member] \| Mizuho Bank Limited [Member]
Note 9 - Notes Payable (Details) [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity			$ 10.6	¥ 1,000,000,000
Long-term Line of Credit	$ 9.9	$ 9.5
Interest-bearing Deposits in Banks and Other Financial Institutions	$ 11.0
Weighted Average Rate Domestic Deposit	0.30%
Line of Credit Facility, Interest Rate During Period	0.46%

Note 9 - Notes Payable (Details) - Notes Payable - USD ($) $ in Thousands	Jun. 30, 2014	Dec. 31, 2013
Mizuho Bank Limited [Member]
Note 9 - Notes Payable (Details) - Notes Payable [Line Items]
Note Payable Fair Value	$ 19,724	$ 19,008
Note Payable Carrying Value	19,724	19,008
SAG [Member]
Note 9 - Notes Payable (Details) - Notes Payable [Line Items]
Note Payable Fair Value	30,984	34,889
Note Payable Carrying Value	29,807	33,712
Note Payable Fair Value	50,708	53,897
Note Payable Carrying Value	49,531	52,720
Notes payable, current	27,790	26,892
Notes payable, non-current	$ 21,741	$ 25,828

Note 10 - Collaboration and License Agreements (Details) $ in Millions	6 Months Ended
	Jun. 30, 2014 USD ($)
Up Front Fee And Milestone Payment Arrangement [Member] \| Takeda [Member]
Note 10 - Collaboration and License Agreements (Details) [Line Items]
Revenue Recognition, Milestone Method, Revenue Recognized	$ 150.0

Note 10 - Collaboration and License Agreements (Details) - Cash Streams and Related Revenue Recognized or Deferred under Abbott Agreement - Abbott [Member] - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2014	Dec. 31, 2013
Collaborative Arrangement [Member]
Collaboration revenue:
Amount Deferred	$ 556	$ 555
Revenue Recognized	20
Foreign Currency Effects	21
Product Sales Revenue [Member]
Collaboration revenue:
Cash Received	12,219
Revenue Recognized	13,300
Accounts Receivable	1,213
Foreign Currency Effects	$ (132)

Note 10 - Collaboration and License Agreements (Details) - Cash Streams and Related Revenue Recognized or Deferred under Takeda Agreement - Takeda [Member]
$ in Thousands

6 Months Ended

Jun. 30, 2014

USD ($)

Reimbursement Of Research And Development Expenses [Member] | Research And Development Revenue [Member]

Collaboration revenue:

Amount Deferred

$ 2,345

Cash Received

5,765

Revenue Recognized

3,484

IncreaseDecreaseInReceivables

(355)

^[1]

Collaborative Arrangement [Member]

Collaboration revenue:

Amount Deferred

955

Revenue Recognized

IncreaseDecreaseInReceivables

^[1]

Product Royalty Revenue [Member]

Collaboration revenue:

Cash Received

28,330

Revenue Recognized

27,389

IncreaseDecreaseInReceivables

(941)

^[1]

Co-promotion revenue [Member]

Collaboration revenue:

Cash Received

371

Revenue Recognized

1,085

IncreaseDecreaseInReceivables

$ 714

^[1]

[1]	Includes billed and unbilled accounts receivable.

Note 11 - Stock Option Plans (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
Note 11 - Stock Option Plans (Details) - USD ($)	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Common Class A [Member] \| 2006 Employee Stock Purchase Plan [Member]
Note 11 - Stock Option Plans (Details) [Line Items]
Stock Issued During Period, Value, Employee Stock Purchase Plan	$ 7,839	$ 6,126	$ 13,226	$ 10,997
Stock Issued During Period, Shares, Employee Stock Purchase Plans (in Shares)	1,196	980	1,989	1,764
Employee Stock Option [Member]
Note 11 - Stock Option Plans (Details) [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition			3 years 40 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)			$ 8.07		$ 7.36
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	$ 3,800,000		$ 3,800,000
Stock Issued During Period, Value, Employee Stock Purchase Plan			$ 13,000

Note 11 - Stock Option Plans (Details) - Employee Stock Option Activity - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2014	Dec. 31, 2013
2001 Incentive Plan [Member]
Note 11 - Stock Option Plans (Details) - Employee Stock Option Activity [Line Items]
Options Outstanding	146,200	146,200
Options Outstanding, Weighted Average Exercise Price Per Share	$ 10.00	$ 10.00
Options Outstanding, Weighted Average Remaining Contractual Term (Years)	1 year 193 days
Options exercisable		146,200
Options exercisable, Weighted Average Exercise Price Per Share		$ 10.00
Options exercisable, Weighted Average Remaining Contractual Term (Years)		1 year 193 days
Stock Incentive Plan 2006 [Member]
Note 11 - Stock Option Plans (Details) - Employee Stock Option Activity [Line Items]
Options Outstanding	2,738,911	2,513,063
Options Outstanding, Weighted Average Exercise Price Per Share	$ 6.14	$ 5.03
Options Outstanding, Weighted Average Remaining Contractual Term (Years)	7 years 295 days
Options Outstanding, Aggregate Intrinsic Value	$ 3,940,531
Options granted	870,000
Options granted	$ 8.07
Options exercised	(370,140)
Options exercised, Weighted Average Exercise Price Per Share	$ 4.41
Options forfeited	(90,984)
Options forfeited	$ 4.42
Options expired	(183,028)
Options expired	$ 4.41
Options exercisable		982,451
Options exercisable, Weighted Average Exercise Price Per Share		$ 5.86
Options exercisable, Weighted Average Remaining Contractual Term (Years)		6 years 262 days
Options exercisable, Aggregate Intrinsic Value		$ 1,805,357
Non Employee Stock Plan 2001 [Member]
Note 11 - Stock Option Plans (Details) - Employee Stock Option Activity [Line Items]
Options Outstanding	342,500	410,000
Options Outstanding, Weighted Average Exercise Price Per Share	$ 5.85	$ 5.85
Options Outstanding, Weighted Average Remaining Contractual Term (Years)	302 days
Options Outstanding, Aggregate Intrinsic Value	$ 359,625
Options exercised	(67,500)
Options exercised, Weighted Average Exercise Price Per Share	$ 5.85
Options exercisable		342,500
Options exercisable, Weighted Average Exercise Price Per Share		$ 5.85
Options exercisable, Weighted Average Remaining Contractual Term (Years)		302 days
Options exercisable, Aggregate Intrinsic Value		$ 359,625

Note 12 - Income Taxes (Details) - USD ($)	3 Months Ended		6 Months Ended
Note 12 - Income Taxes (Details) - USD ($)	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Income Tax Disclosure [Abstract]
Income Tax Expense (Benefit)	$ 1,779,000	$ 4,324,000	$ 3,086,000	$ 5,466,000
Liability for Uncertain Tax Positions, Noncurrent	971,000		971,000
Liability for Uncertain Tax Positions, Current	971,000		971,000
Increase (Decrease) in Income Taxes	$ (81,000)		$ 292,000

Note 13 - Segment Reporting (Details) - Financial Information by Reportable Geographic Segment - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Americas [Member]
Segment Reporting Information [Line Items]
Research and development revenue	$ 1,700	$ 11,461	$ 3,484	$ 14,261
Product royalty revenue	13,888	12,000	27,389	23,677
Product sales revenue	223	106	381	107
Co-promotion revenue	723		1,085	61
Contract and collaboration revenue	141	142	283	283
Total revenues	16,675	23,709	32,622	38,389
Cost of goods sold	146	53	296	76
Research and development expenses	2,243	1,304	4,832	2,586
Depreciation and amortization	186	112	374	234
Other operating expenses	8,839	8,159	16,680	18,476
Income (loss) from operations	5,261	14,081	10,440	17,017
Interest income	22	20	43	35
Interest expense	(352)		(711)
Other non-operating expense, net	5	1	2	(15)
Income (loss) before income taxes	4,936	14,102	9,774	17,037
Capital expenditures	4	17	45	31
As of June 30, 2014
Property and equipment, net	711		711		$ 869
Identifiable assets, net of intercompany loans and investments	106,622		106,622		95,350
Europe [Member]
Segment Reporting Information [Line Items]
Product sales revenue	99	12	155	20
Contract and collaboration revenue	64	10	114	22
Total revenues	163	22	269	42
Cost of goods sold	14	3	39	8
Research and development expenses	1,223	1,941	2,635	4,612
Depreciation and amortization	166	251	332	501
Other operating expenses	2,500	1,130	4,734	1,728
Income (loss) from operations	(3,740)	(3,303)	(7,471)	(6,807)
Interest income	1	2	4	6
Interest expense		(449)		(909)
Other non-operating expense, net	942	(72)	990	(264)
Income (loss) before income taxes	(2,797)	(3,822)	(6,477)	(7,974)
Capital expenditures	2	3	2	106
As of June 30, 2014
Property and equipment, net	99		99		112
Identifiable assets, net of intercompany loans and investments	17,855		17,855		23,843
Asia [Member]
Segment Reporting Information [Line Items]
Product sales revenue	7,221	3,281	13,319	5,489
Contract and collaboration revenue	10	11	20	22
Total revenues	7,231	3,292	13,339	5,511
Cost of goods sold	3,636	1,852	6,854	3,106
Research and development expenses	786	1,180	1,920	2,856
Depreciation and amortization	8	9	15	18
Other operating expenses	511	860	979	2,180
Income (loss) from operations	2,290	(609)	3,571	(2,649)
Interest income		1	33	1
Interest expense	(40)	(44)	(81)	(79)
Other non-operating expense, net	(1,000)	941	(1,368)	2,299
Income (loss) before income taxes	1,250	289	2,155	(428)
Capital expenditures	2		2	3
As of June 30, 2014
Property and equipment, net	169		169		175
Identifiable assets, net of intercompany loans and investments	17,762		17,762		17,684
Research and development revenue	1,700	11,461	3,484	14,261
Product royalty revenue	13,888	12,000	27,389	23,677
Product sales revenue	7,543	3,399	13,855	5,616
Co-promotion revenue	723		1,085	61
Contract and collaboration revenue	215	163	417	327
Total revenues	24,069	27,023	46,230	43,942
Cost of goods sold	3,796	1,908	7,189	3,190
Research and development expenses	4,252	4,425	9,387	10,054
Depreciation and amortization	360	372	721	753
Other operating expenses	11,850	10,149	22,393	22,384
Income (loss) from operations	3,811	10,169	6,540	7,561
Interest income	23	23	80	42
Interest expense	(392)	(493)	(792)	(988)
Other non-operating expense, net	(53)	870	(376)	2,020
Income (loss) before income taxes	3,389	10,569	5,452	8,635
Capital expenditures	8	$ 20	49	$ 140
Property and equipment, net	979		979		1,156
Identifiable assets, net of intercompany loans and investments	$ 142,239		$ 142,239		$ 136,877

Label	Element	Value
Takeda [Member] \| Collaborative Arrangement [Member]
Deferred Revenue	us-gaap_DeferredRevenue	$ 1,029,000
Non-current [Member]
Fair value	us-gaap_AvailableForSaleSecurities	7,460,000
Fair value	us-gaap_AvailableForSaleSecurities	7,219,000
Available-for-sale Securities, Amortized Cost Basis	us-gaap_AvailableForSaleSecuritiesAmortizedCost	7,474,000
Available-for-sale Securities, Amortized Cost Basis	us-gaap_AvailableForSaleSecuritiesAmortizedCost	7,223,000
Unrealized losses	us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss	(14,000)
Unrealized losses	us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss	(4,000)
Current [Member]
Fair value	us-gaap_AvailableForSaleSecurities	14,017,000
Fair value	us-gaap_AvailableForSaleSecurities	16,003,000
Unrealized gains	us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGains	2,000
Unrealized gains	us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGains	3,000
Available-for-sale Securities, Amortized Cost Basis	us-gaap_AvailableForSaleSecuritiesAmortizedCost	14,015,000
Available-for-sale Securities, Amortized Cost Basis	us-gaap_AvailableForSaleSecuritiesAmortizedCost	16,000,000
Fair Value, Inputs, Level 2 [Member]
Assets at fair value	us-gaap_AssetsFairValueDisclosureRecurring	32,402,000
Assets at fair value	us-gaap_AssetsFairValueDisclosureRecurring	33,942,000
Estimate of Fair Value Measurement [Member]
Assets at fair value	us-gaap_AssetsFairValueDisclosureRecurring	39,916,000
Assets at fair value	us-gaap_AssetsFairValueDisclosureRecurring	39,897,000
Fair Value, Inputs, Level 1 [Member]
Assets at fair value	us-gaap_AssetsFairValueDisclosureRecurring	7,514,000
Assets at fair value	us-gaap_AssetsFairValueDisclosureRecurring	5,955,000
Reimbursement Of Research And Development Expenses [Member] \| Takeda [Member] \| Research And Development Revenue [Member]
Deferred Revenue	us-gaap_DeferredRevenue	$ 419,000

Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis - USD ($) $ in Thousands	Jun. 30, 2014	Dec. 31, 2013
US Treasury and Government [Member] \| Fair Value, Inputs, Level 2 [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value	$ 1,000	$ 1,000
US Treasury and Government [Member] \| Estimate of Fair Value Measurement [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value	1,000	1,000
US Government Agencies Debt Securities [Member] \| Fair Value, Inputs, Level 2 [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value	13,208	13,260
US Government Agencies Debt Securities [Member] \| Estimate of Fair Value Measurement [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value	13,208	13,260
Commercial Paper [Member] \| Fair Value, Inputs, Level 2 [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value	7,949	6,449
Commercial Paper [Member] \| Estimate of Fair Value Measurement [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value	7,949	6,449
Certificates of Deposit [Member] \| Fair Value, Inputs, Level 2 [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value	6,250	6,000
Certificates of Deposit [Member] \| Estimate of Fair Value Measurement [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value	6,250	6,000
Corporate Bond Securities [Member] \| Fair Value, Inputs, Level 2 [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value	3,995	5,533
Corporate Bond Securities [Member] \| Estimate of Fair Value Measurement [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value	3,995	5,533
Money Market Funds [Member] \| Fair Value, Inputs, Level 1 [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value	7,514	5,955
Money Market Funds [Member] \| Estimate of Fair Value Measurement [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value	$ 7,514	5,955
Municipal Notes [Member] \| Fair Value, Inputs, Level 2 [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value		1,700
Municipal Notes [Member] \| Estimate of Fair Value Measurement [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value		$ 1,700